Trial Profile
A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2014
Price :
$35
*
At a glance
- Drugs Sifalimumab (Primary)
- Indications Dermatomyositis; Polymyositis
- Focus Adverse reactions
- Sponsors MedImmune
- 19 Dec 2014 New trial record